Know What's Happening in BioTech
Know What's Happening in BioTech
BioTech Pulse
EMAIL DIGESTS
Daily
Every morning
Weekly
Tuesday recap
EMAIL DIGESTS
Daily
Every morning
Weekly
Tuesday recap
Eli Lilly agreed to buy Centessa Pharmaceuticals for up to $7.8 billion, paying $38 per share in cash plus a contingent value right worth up to $9 per share. The announcement lifted Centessa’s Nasdaq price 45% to a 52‑week high, underscoring investor enthusiasm for its orexin‑receptor program and Lilly’s push into sleep‑medicine.
Aubrey de Grey, founder and CSO of the Longevity Escape Velocity Foundation, told listeners of Longevity Technology Unlocked that emerging therapies could rejuvenate people in their 60s back to a biological age of 40, buying roughly 20 years for further...
Agios Pharmaceuticals announced it will seek accelerated U.S. approval for its oral drug mitapivat to treat sickle‑cell disease, prompting a 21.7% rise in its shares. The company has already filed a confirmatory trial proposal with the FDA and is preparing...
The longevity factor spermidine is part of a highly heritable complex erythrocyte phenotype associated with longevity https://t.co/rHT8XoWHFz
Cysteine directs T cells to either multiply or attack tumors by fueling distinct metabolic pathways, suggesting new strategies to fine-tune immune responses in cancer therapy. immunometabolism
Researchers at Henan Academy, Zhengzhou University and Shenzhen University demonstrated that activating the Dectin‑1 receptor on regulatory T cells (Tregs) can reverse their dormant, senescent state and restore anti‑inflammatory function. Using the small peptide KQS‑1, they epigenetically up‑regulated FOXP3 and...
Researchers identified damaging variants in innate immunity genes, especially those governing natural killer (NK) cell activation, as strong modifiers of breast cancer onset in women carrying the BRCA1 185delAG mutation. An analysis of 321 Ashkenazi Jewish carriers showed that these...
The episode delves into the controversy surrounding the FDA’s handling of hydroxychloroquine during the COVID‑19 pandemic, focusing on whistleblower Dr. Rick Bright’s claims that Dr. Janet Woodcock pressured him to pursue an Emergency Use Authorization (EUA) rather than an expanded‑access protocol....
University of Queensland researchers applied spatial multi‑omics to 27 neuroblastoma samples, creating high‑resolution maps that reveal a GPX4‑driven shield protecting tumor cells from ferroptosis and surrounding immune cells acting as "bodyguards." The study, published in Genome Medicine, identifies GPX4 as...
In this episode of Business Game Changers, host Sarah Westall and Dr. Diane Kayser discuss the rapidly evolving peptide market, focusing on the upcoming weight‑loss peptide retatrutide (also called Reditrutide). They explain how big‑pharma is moving to control peptide supplements,...
Researchers at UC San Diego discovered that the inflammatory protein TYK2 acts as a metastasis suppressor in breast cancer by sensing extracellular matrix stiffness. On soft matrices, TYK2 remains on the cell membrane and blocks invasion, while stiff environments cause...
A recent preclinical study identified BIRC5 and MCL‑1 as co‑drivers of survival in mantle cell lymphoma (MCL) and demonstrated that simultaneous inhibition with YM155 and S63845 produces strong synergistic killing of cancer cells. The combination was effective across both treatment‑naïve...
A new longitudinal study of 83 healthy military personnel tracked cardiac biomarkers after two mRNA COVID‑19 vaccine doses. Within two weeks of the second shot, 49% of participants exhibited a rise in NT‑proBNP exceeding 1.5 times their baseline, indicating subclinical...
Stealth biotech startup R3 Bio, backed by billionaire investors, announced a fundraising round to develop non‑sentient monkey organ‑sack platforms for donor organs. Investigative reporting by MIT Technology Review revealed that the founders are also exploring the far more controversial concept...
Soficabtagene geleucel (WU‑CART‑007), an off‑the‑shelf CRISPR‑engineered CAR‑T therapy, received FDA Breakthrough Therapy Designation for relapsed or refractory T‑cell leukemia and lymphoma. In a phase 1/2 trial of 28 patients, the drug achieved a 91% overall response rate and a 73% complete...
Researchers led by Beyene, Wang and Cinel published a landmark lipidomics analysis in Nature Communications that ties distinct lipid profiles to dietary patterns and cardio‑metabolic outcomes, offering a molecular roadmap for precision nutrition.
Kobe University researchers engineered a synthetic right‑handed (D) peptide that binds amyloid‑beta, the disordered protein driving Alzheimer’s plaques, and blocks its aggregation. In mouse brain cell cultures the mirror peptide restored cell viability to 100%, compared with 50% survival when...
Researchers led by Dr. Bedoyan, Dr. Morgan and Dr. Sun completed a phase 1/2 trial that used nuclease‑free homologous recombination to edit the genes of children with methylmalonic acidemia. The therapy lowered toxic metabolite levels and showed durable engraftment without...
The Food and Drug Administration is preparing to reverse its 2023 restriction on dozens of experimental peptides, permitting licensed compounding pharmacies to produce them again. The move follows Health Secretary Robert F. Kennedy Jr.’s public promise on the Joe Rogan...
Nanobiotix posted full‑year 2025 results showing a revenue rebound to roughly $35.5 million and a net loss of $26 million, a 65% YoY improvement. The company secured a non‑dilutive royalty financing of up to $71 million, extending its cash runway to early 2028 with...
Biogen announced a definitive agreement to buy Apellis Pharmaceuticals for $41 a share in cash, valuing the transaction at roughly $5.6 billion. The deal lifts Apellis shares 135.7% to $40.28 and adds two marketed complement‑inhibitor drugs, EMPAVELI and SYFOVRE, to Biogen’s...
Joseph Mikhael, MD, highlights a dramatic shift in multiple myeloma care for older adults, driven by refined frailty assessments and the rise of targeted immunotherapies such as CAR‑T cells and bispecific antibodies. These advances have translated into higher survival rates...
I'd like to draw your attention to my fantastic @statnews colleague @elaineywchen. She led the way our obesity drug coverage, is a host on our podcast, and writes our biotech newsletter most days. Today has two big examples of the...
MIT researchers unveiled a myoneural actuator (MNA) that rewires sensory nerves to transform existing muscle into a fatigue‑resistant, computer‑controlled motor for paralyzed organs. In rodent models the MNA restored intestinal squeezing and mimicked residual calf muscle function while sending sensory...
Genetically modified marmosets lacking the OTOF gene now serve as the first primate model for human congenital deafness, offering a precise platform to advance gene therapies targeting hearing loss. genetherapy
I joined Sam Fazeli for the latest episode of Bloomberg Intelligence's Vanguards of Healthcare podcast and talk about our partnership with Eli Lilly and why I believe algorithmic approaches are reshaping the earliest stages of pharmaceutical R&D. The biggest impact...
Tenpoint Therapeutics announced that Yuvezzi, the first FDA‑approved eye‑drop for presbyopia, is now commercially available in the United States. The formulation combines carbachol 2.75 % and brimonidine tartrate 0.1 % to induce pupil constriction within 30 minutes, providing up to ten hours...
Vanda Pharmaceuticals reported that its NK1‑receptor antagonist tradipitant achieved its primary endpoint in a Phase II trial for gastroparesis, showing a roughly 30% improvement in nausea scores versus placebo. The data suggest the drug could address a sizable unmet need in...
University of Illinois Chicago nutrition professor Krista Varady reported that a six‑hour time‑restricted eating protocol reduced testosterone, lowered free androgen index and improved A1C in a six‑month trial of 76 women with PCOS, while participants lost an average of 10 pounds....
Scientists have identified pseudaminic acid, a sugar found only on the surface of certain Gram‑negative bacteria, as a vulnerable target. By synthesizing this sugar and creating monoclonal antibodies that bind it, researchers demonstrated in mice that the antibodies flag the...
Scientists at the University of Barcelona Institute of Neurosciences have demonstrated that the novel compound FLAV-27 can reverse cognitive decline in mice engineered to develop Alzheimer's disease. The breakthrough, which targets the brain enzyme EHMT2 to reprogram neuronal epigenetics, offers...
Stanford researchers engineered natural killer (NK) and cytotoxic T cells to overexpress metabolite‑sensing G protein‑coupled receptors, most notably GPR183, enabling the cells to home toward tumor‑derived metabolic cues. In mouse models of triple‑negative breast and ovarian cancer, GPR183‑enhanced NK‑92 cells...
Researchers reviewed polysaccharide‑based microneedles as a platform for cancer immunotherapy, emphasizing how additive manufacturing—particularly high‑resolution 3D printing—can create customizable transdermal delivery arrays. Natural polymers such as hyaluronic acid, chitosan and alginate provide biocompatibility and enable dissolvable or hydrogel‑based needles with...
Alamar Biosciences, the Fremont‑based proteomics company, filed to go public on Nasdaq after raising $128 million in a Series C round and adding almost 100 employees in two years. The move marks the firm’s transition from research‑focused labs to commercial sales of...
If the FDA follows through with lifting restrictions on several peptides, it could unlock a massive market opportunity in performance medicine. One of the most interesting candidates IMHO – with all the bias I have as one of the founders -...
Genetically modified pig livers have entered early clinical testing, with a Chinese patient surviving 171 days after transplantation. Researchers in China are exploring pig livers as auxiliary support, while a University of Pennsylvania team is evaluating extracorporeal pig livers as...
Elecoglipron (ECC5004/AZD5004), an oral small‑molecule GLP‑1 receptor agonist, completed Phase 2 trials in type 2 diabetes and obesity, meeting primary endpoints in the SOLSTICE and VISTA studies. AstraZeneca licensed global rights from Eccogene for an upfront payment of $185 million and potential milestones...
NutraIngredients is inviting consumer‑facing, science‑driven startups and researchers to submit entries for its Probiota Pioneers and Scientific Frontiers tracks, with winners presenting at Probiota Americas in Vancouver from June 8‑10, 2026. Startups must be Americas‑based, under 20 employees, founded within ten years...
CellCentric has launched the pivotal Phase 2 DOMMINO‑1 trial of inobrodib 20 mg combined with pomalidomide and dexamethasone (InoPd) in heavily pretreated relapsed or refractory multiple myeloma (RRMM) patients. The first dose was administered at The Royal Marsden in London, with additional...
ImmunityBio secured $75 million of non‑dilutive financing under its existing royalty‑interest purchase agreement with Oberland Capital, raising total committed capital to $375 million. At the same time, Nant Capital converted $25 million of debt into common stock, reducing the company’s liabilities. The combined...
Data, data, data... The @enhanced_games are so much more than just another sports event... "The peptide community has a credibility problem and an evidence problem. Millions of people use compounds backed by rodent studies and Reddit threads. The FDA is cracking...
A phase IIa trial published in Nature Medicine found that a single intravenous dose of dimethyltryptamine (DMT), paired with structured psychotherapy, produced a rapid and sustained reduction in major depressive disorder symptoms. Participants receiving 21.5 mg of DMT showed an average...
AN2 Therapeutics has begun a Phase 2 investigator‑initiated trial of epetraborole, an oral leucyl‑tRNA synthetase inhibitor, for pulmonary disease caused by Mycobacterium abscessus. The randomized, double‑blind study will enroll 84 patients across roughly 10‑15 U.S. sites and is led by Dr. Kevin...
Artificial intelligence is reshaping clinical development by augmenting, not replacing, human expertise. AI already accelerates medical imaging, compound discovery and COVID‑19 vaccine modeling, compressing timelines from years to months. In clinical outcome assessment (COA) translation, AI can support draft translation...
As a medical school professor, this is one of the most paradigm-shifting findings I've seen this year. Weill Cornell researchers discovered that a single bacterial gene in your gut determines whether the amino acid asparagine fuels tumor growth or supercharges your...
Forget Antibiotics: These Killer Cells Wipe Out Deadly Superbugs in a Day by @ShellyFan https://t.co/KVAaK61555 https://t.co/cXP8loNRHn
Mayo Clinic and Wayne State scientists report that post‑menopausal women who combined tirzepatide with hormone therapy lost 35% more body weight than those on tirzepatide alone. The retrospective analysis of 120 women showed an average 19.2% loss versus 14%, prompting...
Inspired by Mother Nature, Discovering New Drugs. @viswacolluru of @lifeschemistry is the latest guest on The Long Run. Sponsored by @AlphaSenseInc and Dash Bio. https://t.co/F01HMam6Ul
